In 251 adults with atopic dermatitis, delgocitinib cream 1 to 20 mg/g twice daily for 8 weeks lowered EASI dose-dependently vs vehicle (-5.0 to -7.6 vs -1.9; all P<0.05). Adverse events were similar between groups.
RCTn = 251
Silverberg et al. Delgocitinib cream formulation demonstrates a dose-dependent response in adults with mild to severe atopic dermatitis: results from an 8-week randomized phase IIb trial